In a helpful video, Prof. Dr Anne Demols, an expert in digestive oncology at Cliniques Universitaires de Bruxelles – Hôpital Erasme, presented the latest findings from several studies on gastric, pancreatic, and hepatobiliary cancer.
The phase 3 KEYNOTE-966 study of pembrolizumab plus gemcitabine and cisplatin versus placebo plus gem/cis for advanced biliary tract cancer reported health-related quality of life data.
The phase III IMbrave050 trial of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablation revealed efficacy, safety, and patient-reported outcomes.
Additionally, Prof. Demols shared the outcomes of the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma, where immune-mediated adverse events with tremelimumab plus durvalumab occurred.
The phase 3 NAPOLI 3 trial reported 12- and 18-month survival rates from liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma.
The SGNTUC-019 basket study and the HERIZON-BTC-02 study reported results for the first time. SGNTUC-019 on tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer and HERIZON-BTC-02 on zanidatamab in previously-treated HER2-amplified biliary tract cancer.
With the educational support of:
